Disclosures for "CSM-101 is a Brain-penetrant Small Molecule Agonist of TRPML1 for Parkinson’s-related Disorders"
-
Mr. Murphy has or had stock in Casma Therapeutics.
-
Mr. Garcia Fortanet has received personal compensation for serving as an employee of DEM BioPharma. Mr. Garcia Fortanet has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Casma Therapeutics. Mr. Garcia Fortanet has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. BAIRD has received personal compensation for serving as an employee of Casma Therapeutics. Dr. BAIRD has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Third Rock Ventures.
-
Mr. Lehmberg has received personal compensation for serving as an employee of Casma Therapeutics . Mr. Lehmberg has received personal compensation for serving as an employee of Interdict Bio. Mr. Lehmberg has stock in Casma Therapeutics. Mr. Lehmberg has stock in Interdict Bio.
-
Ms. Skerry has received personal compensation for serving as an employee of Apellis. Ms. Skerry has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Casma. Ms. Skerry has stock in Apellis. Ms. Skerry has stock in UnitedHealth Group.
-
Dr. Broadus has received personal compensation for serving as an employee of Casma Therapeutics. Dr. Broadus has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Casma Therapeutics. Dr. Broadus has stock in Casma Therapeutics.